Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 31 Carcinoma, Hepatocellular 30 Neoplasms 19 Carcinoma, Renal Cell 16 Melanoma 10 Carcinoma, Non-Small-Cell Lung 10 Thyroid Neoplasms 9 Endometrial Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 6 Colorectal Neoplasms 5 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Liver Neoplasms 4 Carcinoma, Transitional Cell 4 Uterine Cervical Neoplasms 3 Small Cell Lung Carcinoma 3 Recurrence 3 Lymphoma 3 Esophageal Squamous Cell Carcinoma 3 Esophageal Neoplasms 3 Carcinoma 3 Biliary Tract Neoplasms 3 Stomach Neoplasms 2 Solid Tumors 2 Osteosarcoma 2 Lung Neoplasms 2 Kidney Neoplasms 2 Glioma 2 Diabetes Mellitus, Insulin-Dependent, 12 2

Interventions

Azacitidine 14 venetoclax 10 AP 1903 reagent 7 Rituximab 6 Dexamethasone 6 Itraconazole 5 Cytarabine 5 Bortezomib 5 fludarabine 4 fedratinib 4 belinostat 4 Nivolumab 4 Lenalidomide 4 Imatinib Mesylate 4 Daunorubicin 4 ARQ531 4 pomalidomide 3 ibrutinib 3 daratumumab 3 cc-486 3 angiotensin I (1-7) 3 Standard of Care 3 GSK2110183 3 Cyclophosphamide 3 zanubrutinib 2 tosedostat 2 tazemetostat 2 tanespimycin 2 talquetamab 2 tafasitamab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Hematologic Neoplasms × lenvatinib × Clear all

NCT03486873 2026-06-05

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡